Preclinical Development for Personalized Therapy Using Disease-Relevant Cell Models
- N1C Moderator
- Jun 15, 2024
- 2 min read
Updated: Jul 16, 2024
Monday, July 15 2024, 12:30 pm US EDT
iXCells Biotechnologies is specialized in providing innovative pre-clinical drug discovery solutions with the focus on disease-relevant cell models. We have been working with multiple rare disease advocacy groups for development of personalized therapy with different modalities (ASO, small molecule repurposing, gene therapy) in a variety of cell lines, including primary cells and patient-derived iPSC models. In this presentation, we will discuss the selection of different cell models and general design for preclinical development of personalized medicine.
Nianwei Lin received his Ph.D. in genetics from the College of Medicine at the University of Florida. He was trained with a background in apoptotic cell death using Drosophila as the genetic model. In 2011, Nianwei started his postdoctoral training at Sanford-Burnham Medical Research Institute, where he went on to study the self-renewal and differentiation control of embryonic stem cells and focused his research on long noncoding RNAs (lncRNA) mediated regulation. Nianwei joined DSRD team at Pfizer as a postdoctoral fellow in August 2014, with his work focused on effects of lysosomal dysfunction on membrane trafficking and signal transduction, as well as the
implication in toxicity, efficacy and resistance development.
In 2014, Nianwei and his business partners foundediXCells Biotechnologies, a cell biology and cell technology company dedicated to providing innovative pre-clinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate drug discovery processes. The company offers the customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and execution. The company is specialized in development of Disease-in-a-dish models with its expertise in iPSC engineering and primary cell isolation for pre-clinical applications, including toxicology testing, personalized medicine development, target-based or phenotypic screening, etc..
My husband was diagnosed with Creutzfeldt-Jakob Disease (CJD) four years ago. For over two years, we relied on prescription medications and therapies, but unfortunately, his symptoms continued to worsen. His memory, coordination, and overall strength declined, and everyday life became increasingly difficult.Last year, out of desperation and hope, we decided to try an herbal treatment program from NaturePath Herbal Clinic. Honestly, we were skeptical at first, but within a few months of starting the treatment, we began to notice real changes. His alertness improved, his movements became steadier, and he regained a surprising amount of energy and clarity.Incredibly, he also regained much of his independence and confidence. It’s been a life-changing experience he feels more like himself again, better than…